Researchers from Johns Hopkins University have filed for protection of their Optimal Target Identification via Modelling of Arrhythmogenesis technology – a method that builds a model of a patient’s heart from a cardiac MRI.
RTI International has divulged vancomycin derivatives with siderophore modification reported to be useful for the treatment of gram-negative and gram-positive bacterial infections.
Nutshell Biotech (Shanghai) Co. Ltd. has identified nitrogen-containing macrocyclic compounds acting as DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.
Scientists at CeMM-Forschungsinstitut für Molekulare Medizin GmbH and Max Planck Society for the Advancement of Science EV have synthesized proteolysis targeting chimera (PROTAC) compounds comprising a DDB1- and CUL4-associated factor 11 (DCAF11) binding moiety covalently linked to a different protein targeting moiety through a linker.
Researchers from Stanford University have filed for protection of their use of mechanotransduction inhibitors in coatings for surgical sutures to reduce scarring.
Thirtyfivebio Ltd. has described G protein-coupled receptor GPR35 antagonists reported to be useful for the treatment of cancer, fibrosis, inflammatory, cardiovascular, gastrointestinal and immunological disorders.
Humanwell Healthcare (Group) Co. Ltd. has identified kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of atopic dermatitis, autoimmune disease, cancer, Crohn’s disease, psoriasis and ulcerative colitis.
Astrazeneca AB has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon unit coupled to an androgen receptor (AR) targeting moiety via a linker acting as AR degradation inducers reported to be useful for the treatment of cancer.